Analysis of the ovarian (infundibulopelvic) ligament removed during ovarian cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational pathology study that examines infundibulopelvic ligament tissue resected as part of complete staging surgery in patients with epithelial ovarian cancer. Researchers will analyze the ligament specimens for tumor involvement and correlate those findings with para‑aortic lymph node status and patient outcomes. Eligible patients include those undergoing primary or interval complete staging surgery (hysterectomy, bilateral salpingo‑oophorectomy, pelvic and para‑aortic lymphadenectomy, omentectomy) with no residual disease and ECOG 0–1. The goal is to determine whether ligament involvement is associated with metastatic spread and survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma.

  * FIGO 2014 stage IA-IVB.
  * Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy
  * Patients with no residual disease after surgery.
  * Patients with ECOG performance status 0-1.

Exclusion Criteria:

* ◦ Patients without epithelial ovarian cancer.

  * Patients with ECOG 2-4.
  * Patients who do not consent to participate in the study.
  * Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.

Where it's running

• Complejo Universitario Insular Materno Infantil de Las Palmas
  Las Palmas de Gran Canaria, Spain Recruiting

Study contacts

• Study coordinator: beatriz NAVARRO SANTANA, pHD
• Email: bea_0904@hotmail.com
• Phone: +34620151146

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trastuzumab deruxtecan versus standard treatment for ovarian cancer that returned after PARP inhibitor therapy

  This study will test whether trastuzumab deruxtecan helps people with HER2-expressing recurrent ovarian, fallopian tube, or peritoneal cancer that progressed on prior PARP inhibitor therapy compared with standard chemotherapy or bevacizumab.

  Recruiting Phase 2 Yonsei University · Seoul, Seoul · NCT07340164

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• VT-101 in Advanced Ovarian Cancer: early safety study in adults

  This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07905677

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.